SCHEDULE 13G/A: Kynam Capital Management Discloses 9.79% Stake in Celldex Therapeutics

Kynam Capital Management, LP, along with its general partner and managing member, has disclosed a significant 9.79% beneficial ownership stake in Celldex Therapeutics, Inc.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have filed a Schedule 13G, indicating beneficial ownership in Celldex Therapeutics, Inc.
• The filing reports an aggregate beneficial ownership of 6,500,000 shares of Celldex Therapeutics, Inc. Common Stock.
• This ownership represents 9.79% of the class of securities.
• The reporting persons, including Kynam Capital Management, LP (an Investment Adviser), Kynam Capital Management GP, LLC (Other), and Yue Tang (an Individual), share both voting and dispositive power over all 6,500,000 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by Kynam Capital Management in Celldex Therapeutics, a company operating in the biotechnology sector. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, reflecting their investment strategies within the broader healthcare and life sciences industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock's trading volume or price.

Key Dates

Keywords

Celldex Therapeutics, Kynam Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals